Table 1.
Baseline characteristics of individuals starting antiretroviral therapy, comparing those who did vs. did not receive isoniazid preventive therapy (n=3270).
| Baseline characteristic | No IPT N (%) |
IPT N (%) |
P value |
|---|---|---|---|
| All | 2348 | 922 | |
|
| |||
| Age (years) | |||
| Median (IQR) | 45 (38 – 51) | 46 (37 – 52) | P2=0.25 |
| 18 – 29 | 220 (9.4) | 93 (10.1) | P1=0.005 |
| 30 – 39 | 740 (31.5) | 269 (29.2) | |
| 40 – 49 | 965 (41.1) | 346 (37.5) | |
| ≥ 50 | 423 (18.0) | 214 (23.2) | |
|
| |||
| Gender: number (%) male | 2182 (92.9) | 857 (94.0) | P1=0.26 |
|
| |||
| Baseline CD4 count* (cells/μl) | |||
| Median (IQR) | 152 (81 – 224) | 158 (98 – 215) | P2=0.56 |
| <50 | 323 (14.6) | 95 (10.7) | P1=0.002 |
| 50 – 100 | 383 (17.3) | 138 (15.5) | |
| 101 – 150 | 385 (17.5) | 182 (20.5) | |
| 151 – 200 | 395 (17.9) | 194 (21.8) | |
| >200 | 718 (32.6) | 281 (31.6) | |
|
| |||
| Baseline WHO stage | |||
| 1 or 2 | 1167 (49.7) | 648 (70.3) | P1<0.001 |
| 3 | 873 (37.2) | 233 (25.3) | |
| 4 | 308 (13.1) | 41 (4.5) | |
|
| |||
| Baseline viral load** (copies/ml) | |||
| Median (IQR) | 52,071 (19,134–141,461) | 42,418 (15,420–97,844) | P2<0.001 |
| VL>100 000 | 654 (33.1) | 202 (24.3) | P1<0.001 |
|
| |||
| Baseline haemoglobin*** (g/dl) | |||
| Median (IQR) | 12.9 (11.2–14.1) | 13.4 (12.2 – 14.6) | P2<0.001 |
| Haemoglobin<10 | 250 (13.0) | 50 (5.9) | P1<0.001 |
|
| |||
| Previous tuberculosis | 211 (8.9) | 23 (2.5) | P1<0.001 |
|
| |||
| Cotrimoxazole started | 603 (25.7) | 735 (79.7) | P1<0.001 |
|
| |||
| Year started ART | |||
| 2004 | 633 (27.0) | 91 (9.9) | P1<0.001 |
| 2005 | 587 (25.0) | 181 (19.6) | |
| 2006 | 692 (29.5) | 284 (30.8) | |
| 2007 | 436 (18.6) | 366 (39.7) | |
|
| |||
| Company | |||
| Company A | 2165 (92.2) | 484 (52.5) | P1<0.001 |
| Company B | 78 (3.3) | 347 (37.6) | |
| Company C | 105 (5.5) | 91 (10.0) | |
|
| |||
| Viral response at 6wks**** | 1101 (82.7) | 547 (83.6) | P1=0.58 |
IPT: isoniazid preventive therapy; IQR: interquartile range; ART: antiretroviral therapy
*
available in 3094 individuals
**
available in 2806 individuals
***
available for 2771 individuals
****
>1 log reduction in viral load at 6 weeks after ART initiation, available for 1986 individuals
P1= Pearson chi-squared test
P2=Wilcoxon rank-sum (Mann-Whitney) test